Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis

荟萃分析 神经组阅片室 神经学 医学 肌萎缩侧索硬化 变化(天文学) 入射(几何) 系统回顾 梅德林 病理 精神科 疾病 生物 光学 物理 生物化学 天体物理学
作者
Lu Xu,Tanxin Liu,Lili Liu,Xiaoying Yao,Lu Chen,Dongsheng Fan,Siyan Zhan,Shengfeng Wang
出处
期刊:Journal of Neurology [Springer Science+Business Media]
卷期号:267 (4): 944-953 被引量:223
标识
DOI:10.1007/s00415-019-09652-y
摘要

Amyotrophic lateral sclerosis (ALS) is a global disease, which adversely affects the life quality of patients and significantly increases the burden of families and society. We aimed to assess the changing incidence, prevalence of ALS around the world. We searched Medline, Embase, Web of Science, and Cochrane library to identify articles published until September 9, 2018. Each included study was independently reviewed for methodological quality by two reviewers. We used a random-effects model to summarize individual studies and assessed heterogeneity (I2) with the χ2 test on Cochrane’s Q statistic. We identified 124 studies that were eligible for final inclusion, including 110 studies of incidence and 58 studies of prevalence. The overall crude worldwide ALS prevalence and incidence were 4.42 (95% CI 3.92–4.96) per 1,00,000 population and 1.59 (95% CI 1.39–1.81) per 1,00,000 person-years, respectively. ALS prevalence and incidence increased by age until the age of 70–79. Since 1957, incidence has been significantly rising year by year, and this upward trend was weakened after standardization. The longest survival time were in Asia (ranging from 3.74 years in South Asia to 9.23 years in West Asia). With the aggravation of population aging and the rapid growth of economy, developing regions following the development pattern of the developed regions may suffer rising ALS prevalence and incidence which may increase their disease burden as well. These data highlight the need for research into underlying mechanism and innovations in health-care systems.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
852应助Lou采纳,获得10
1秒前
云帆完成签到,获得积分10
10秒前
于思枫完成签到,获得积分10
12秒前
感性的夜玉完成签到,获得积分10
14秒前
科研通AI5应助科研通管家采纳,获得10
15秒前
烟花应助科研通管家采纳,获得10
15秒前
15秒前
皮肤科应助科研通管家采纳,获得10
15秒前
15秒前
Lucas应助科研通管家采纳,获得10
15秒前
Jasper应助科研通管家采纳,获得30
15秒前
wanci应助科研通管家采纳,获得10
15秒前
HEIKU应助科研通管家采纳,获得20
15秒前
科研通AI5应助科研通管家采纳,获得10
15秒前
ding应助科研通管家采纳,获得10
15秒前
JamesPei应助科研通管家采纳,获得10
15秒前
15秒前
araul应助科研通管家采纳,获得10
15秒前
SciGPT应助科研通管家采纳,获得10
15秒前
科研通AI5应助科研通管家采纳,获得30
16秒前
皮肤科应助科研通管家采纳,获得40
16秒前
所所应助科研通管家采纳,获得10
16秒前
科目三应助科研通管家采纳,获得10
16秒前
16秒前
16秒前
16秒前
LLLLL完成签到,获得积分20
18秒前
llllllllllll发布了新的文献求助10
21秒前
TX完成签到,获得积分10
22秒前
23秒前
Lou发布了新的文献求助10
23秒前
在水一方应助LLLLL采纳,获得10
24秒前
Lou完成签到,获得积分10
31秒前
甘雪娜应助秭归子归采纳,获得10
31秒前
杨小博完成签到 ,获得积分10
33秒前
阿晴完成签到 ,获得积分10
33秒前
游戏人间完成签到 ,获得积分10
37秒前
41秒前
搜集达人应助阿白采纳,获得10
42秒前
42秒前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
ISCN 2024 – An International System for Human Cytogenomic Nomenclature (2024) 3000
Continuum Thermodynamics and Material Modelling 2000
Encyclopedia of Geology (2nd Edition) 2000
105th Edition CRC Handbook of Chemistry and Physics 1600
Maneuvering of a Damaged Navy Combatant 650
China—Art—Modernity: A Critical Introduction to Chinese Visual Expression from the Beginning of the Twentieth Century to the Present Day 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3777008
求助须知:如何正确求助?哪些是违规求助? 3322389
关于积分的说明 10210090
捐赠科研通 3037746
什么是DOI,文献DOI怎么找? 1666872
邀请新用户注册赠送积分活动 797711
科研通“疑难数据库(出版商)”最低求助积分说明 758040